Vectura, Skyepharma To Form World Respiratory Leader

A UK-based global leader in respiratory therapies will be created by Vectura Group PLC's planned purchase of SkyePharma PLC in a friendly, all-stock deal to forge a combined group with estimated market capitalization of just over £1bn, joint sales of £153.9m and profits of around £50.5m.